BioSpace News Archive

Celerion announced today the multimillion-dollar expansion of specialized pharmacies across their clinical research units in North America, demonstrating their commitment to further assisting sponsors in meeting the forthcoming USP requirements for compounding investigational drug product in support of early phase clinical trial research.

First presentation of Alpine’s Variant Tumor Necrosis Factor (TNF) Receptor Domain (vTD) Program demonstrating expanded applicability of its directed evolution platform

OBIO’s Health to Business Bridge™ Program (H2BB) prepares new hires for careers in Ontario’s health science industry, helping companies build for the future in an innovative sector poised for growth.

Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced signing of a collaboration agreement. The two companies have agreed to explore the anti-tumor efficacy of the CD40 antibody mitazalimab (Alligator Bioscience) in combination with SCO-101 (Scandion Oncology) as an addition to

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Alison Lawton, President and Chief Executive Officer, will participate in a fireside chat during the virtual Goldman Sachs 41 st Annual Global Healthcare Conference on Thursday, June 11, 2020 at 11:20 a.m. ET. A live webcast will be availab

Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, today announced that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will guide clinical development of its lead clinical-stage

June 4, 2020 12:00 UTC Aimmune Therapeutics to Present at the Goldman Sachs 41 st Annual Global Healthcare Conference